Skip to content
View pujana-lab's full-sized avatar
3 followers · 0 following

Block or report pujana-lab

Block user

Prevent this user from interacting with your repositories and sending you notifications. Learn more about blocking users.

You must be logged in to block users.

Maximum 250 characters. Please don’t include any personal information such as legal names or email addresses. Markdown is supported. This note will only be visible to you.
Report abuse

Contact GitHub support about this user’s behavior. Learn more about reporting abuse.

Report abuse
pujana-lab/README.md

Pujana Lab

Breast Cancer Group · ProCURE Program, Catalan Institute of Oncology (ICO) Bellvitge Institute for Biomedical Research (IDIBELL) · Girona Institute for Biomedical Research (IDIBGI)

We investigate the biological factors that determine the onset of hereditary breast cancer and translate these findings into mechanism-based, personalized prevention/interception strategies, with a particular focus on BRCA1/2-associated disease.

About the PI

Dr. Miquel Angel Pujana is Senior Researcher at the Catalan Institute of Oncology (ICO), where he leads the Breast Cancer Group within the ProCURE Program, and Principal Investigator at IDIBELL (Barcelona) and IDIBGI (Girona). His research focus is on hereditary breast cancer, investigating BRCA1/2-associated breast cancer from genetic, molecular, cellular, preclinical, and translational perspectives.

His research integrates functional genomics, experimental cancer biology, genetically engineered mouse models, and clinically annotated patient cohorts to elucidate the earliest determinants of breast tumorigenesis and evolution, and to translate these discoveries into mechanism-based interception strategies. The group has contributed to understanding the genetic architecture of breast cancer risk, BRCA1/2 function, tumor initiation, immune evasion, and genetic risk modification.

He is an active contributor to the international Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).

Research focus

  • Biological factors determining breast cancer onset in BRCA1/2 carriers
  • Personalized prevention/interception strategies, including drug repurposing
  • Genetic and inherited modifiers of hereditary cancer risk
  • Precision genomics and risk estimation for breast and ovarian cancer
  • Functional genomics and genetically engineered mouse models

The group also investigates the biology and therapeutic vulnerabilities of lymphangioleiomyomatosis, a metastatic rare disease with biological similarities to breast cancer.

Selected publications

Contact

  • PI: Miquel Angel Pujana
  • Institution: ICO (ProCURE Program) · IDIBELL–IDIBGI
  • ORCID: 0000-0003-3222-4044
  • Google Scholar: Profile

Pinned Loading

  1. cellSim cellSim Public

    Domain-driven C++20 agent-based simulator of BRCA1-mutant tumor initiation, calibrated against clinical penetrance data via ABC-SMC Bayesian inference.

    C++

  2. stochastic_sim stochastic_sim Public

    Gillespie stochastic-simulation model of BRCA1-mutant tumor clone dynamics, tracking wild-type, mutant, immune, and exhausted-immune populations under logistic crowding and immune interaction.

    Python